You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Disitamab Vedotin

Showing 1 - 25 of 280
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin combined with Sintilimab
  • (no location specified)
Jul 2, 2023

Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

Recruiting
  • Gastric Cancer
  • HER2-low-expressing Gastric Cancer
  • Shanghai, China
    Shanghai East Hospital
Oct 9, 2023

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

RC48-ADC in Breast Cancer

Not yet recruiting
  • Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 30, 2023

Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin plus pyrotinib or naratinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin Combined With Sintilimab
  • (no location specified)
Jan 31, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +10 more
Nov 23, 2023

Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Guanzhou, China
    SunYat-senU
May 5, 2023

Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • disitamab vedotin
  • +4 more
  • (no location specified)
Jun 9, 2023

Advanced Breast Cancer Trial (Disitamab vedotin)

Not yet recruiting
  • Advanced Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 16, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)

Not yet recruiting
  • Carcinoma, Squamous Cell of Head and Neck
  • +3 more
  • disitamab vedotin
  • (no location specified)
Aug 15, 2023

Breast Cancer Trial in Chengdu (Disitamab Vedotin, Penpulimab)

Not yet recruiting
  • Breast Cancer
  • Chengdu, Chengdu, Sichuan, China, China
    West China Hospital, Sichuan University
Feb 9, 2023

Urothelial Carcinoma Trial (Disitamab Vedotin, radiotherapy)

Not yet recruiting
  • Urothelial Carcinoma
  • Disitamab Vedotin
  • radiotherapy
  • (no location specified)
Jun 20, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin
  • +3 more
  • (no location specified)
Nov 17, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)

Recruiting
  • Neoadjuvant Immunotherapy
  • Tianjin, China
    The Second Hospital of Tianjin Medical University
Apr 20, 2023

Radical Cystectomy, Urothelial Carcinoma Trial in Wuhan (Disitamab Vedotin and Gemcitabine)

Recruiting
  • Radical Cystectomy
  • Urothelial Carcinoma
  • Disitamab Vedotin and Gemcitabine
  • Wuhan, Hubei, China
  • +1 more
Feb 9, 2023

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,

Recruiting
  • Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Disitamab Vedotin Tislelizumab
  • Disitamab Vedotin
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 9, 2022

Colorectal Tumors Trial (Pembrolizumab, Disitamab vedotin)

Not yet recruiting
  • Colorectal Neoplasms
  • (no location specified)
Apr 19, 2022

Bladder Cancer Trial (Disitamab Vedotin for Injection,Penpulimab Injection)

Not yet recruiting
  • Bladder Cancer
  • Disitamab Vedotin for Injection,Penpulimab Injection
  • (no location specified)
Aug 2, 2022

Colorectal Tumors Trial in China (Disitamab vedotin, Tislelizumab)

Recruiting
  • Colorectal Neoplasms
  • Changzhou, Jiangsu, China
  • +5 more
Aug 7, 2022